Acadia Pharmaceuticals Inc. (ACAD) is a publicly traded Healthcare sector company. As of July 15, 2026, ACAD trades at $25.94 with a market cap of $4.36B and a P/E ratio of 11.63. ACAD moved +1.67% today. Year to date, ACAD is -2.96%; over the trailing twelve months it is +17.76%. Its 52-week range spans $13.40 to $28.35. Analyst consensus is buy with an average price target of $32.21. Rallies surfaces ACAD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ACAD combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $25.94 |
| Market Cap | $4.36B |
| P/E Ratio | 11.63 |
| EPS | $2.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.35 |
| 52-Week Low | $13.40 |
| Volume | 975.60K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.10B |
| Net Income | $375.65M |
| Gross Margin | 91.47% |
15 analysts cover ACAD: 0 strong buy, 11 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $32.21.